Clinical trials: Docetaxel
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
This study is open to adults with specific types of advanced soft tissue sarcoma. People with undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) can join the study if they have a normal version of the TP53 gene.
- Conditions
- Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
- Trial name
- NCT06370871
- Testing
- Brigimadlin, Ezabenlimab, Gemcitabine
- Sponsor
- Boehringer Ingelheim
Disease Free Survival
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
To verify the clinical efficacy and safety of bevacizumab in treating local advanced cervical cancer, present study was designed to investigate the clinical results of bevacizumab combined with concurrent chemoradiotherapy (CCRT)…
- Trial name
- NCT04138992
- Testing
- bevacizumab, DDP, Docetaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Air Force Military Medical University, China
Head and Neck Cancer
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
This is a study for patients who have head and neck cancer that has recurred in the body area where they previously received radiation, and for whom surgery is not planned.
- Trial name
- NCT00713219
- Testing
- IMRT, cetuximab, docetaxel
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer, Gastroesophageal Junction Cancer
GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)
This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in…
- Trial name
- GRACE-DE (NCT07882212)
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Head and Neck Neoplasms
Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma
To assess the efficacy of docetaxel, cisplatin combination in terms of disease free survival. Time to progression of the disease in terms of local and distant failure; assess the survival time, and assess the objective (clinical…
- Trial name
- Tax-Nazo (NCT00772681)
- Testing
- docetaxel and cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 57 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
Lung Cancer
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
The goal of this clinical trial is to explore the efficacy and safety of denosumab in combination with tislelizumab and chemotherapy in the second-line treatment of immuno-experienced patients with EGFR/ALK/ROS1-negative advanced…
- Trial name
- NCT06749886
- Testing
- Denosumab, tislelizumab, Docetaxel
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer, Lung Cancer
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT05137067
- Testing
- Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Optimal Health Research
Breast Cancer
Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, docetaxel, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00801411
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 2 sites in Singapore
- Volunteers
- 318 people
- Sponsor
- National Cancer Centre, Singapore
Gastric Cancer
Study of Weekly DCF to Treat Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy of weekly docetaxol combined with cisplatin and 5-Fu in patients with AGC.
- Trial name
- NCT00568971
- Testing
- Docetaxel, Cisplatin, 5-Fu
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Pancreatic Cancer
Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
RATIONALE: Calcitriol may cause pancreatic cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00238199
- Testing
- calcitriol, docetaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Non-small Cell Lung Cancer
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5.
- Trial name
- NT-NAP-102-1 (NCT04880863)
- Testing
- NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- NeoTX Therapeutics Ltd.
Bladder Cancer, BCG
Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients
Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do…
- Conditions
- Bladder Cancer, BCG, Gemcitabine, Docetaxel
- Trial name
- NCT06374914
- Testing
- Intravesical Solution
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Dokuz Eylul University
Metastatic Prostate Cancer
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Background: Prednisone and docetaxel have been used successfully in treating patients with prostate cancer, either when used alone or in combination with other agents.
- Trial name
- NCT00942578
- Testing
- Bevacizumab, Lenalidomide, Docetaxel
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially…
- Trial name
- NCT06424899
- Testing
- Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zeng Jian
Breast Cancer, Fever
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.
- Conditions
- Breast Cancer, Fever, Neutropenia
- Trial name
- NCT00115414
- Testing
- pegfilgrastim, docetaxel, doxorubicin
- Sponsor
- Amgen
Head and Neck Cancer, Carcinoma, Squamous
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size
- Trial name
- NCT00591149
- Testing
- Oxaliplatin, Docetaxel, Cetuximab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Kansas Medical Center
Prostatic Neoplasm
An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
Study of Biweekly Docetaxel plus Androgen-Deprivation Therapy (ADT) in Patients with Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
- Trial name
- NCT03061643
- Testing
- Docetaxel, Androgen-Deprivation Therapy (ADT)
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Samsung Medical Center
Prostate Cancer
CTC Immune Checkpoint
This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and…
- Trial name
- NCT02456571
- Testing
- CTC biomarker expression prevalence
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.